TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04255992

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Arm
Description: 1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D/Calcium
Description: 1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study: NCT01427127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramosetron
Description: Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
Study: NCT00958191

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident® X3 Polyethylene Insert
Description: Trident® X3 Polyethylene Insert
Study: NCT02521168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine
Description: Oral triiodothyronine is given peri-operatively through naso-gastric tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of saccharin lactis that has the same appearance as Tetronine
Study: NCT03174808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
Study: NCT02736929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy - Cognitive
Description: CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
Study: NCT04130880

Intervention type: DIAGNOSTIC_TEST
Intervention: Turkish Montreal Children's Hospital Feeding Scale
Description: The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Turkish Montreal Children's Hospital Feeding Scale
Description: The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
Study: NCT00515099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Daily 4-day escalating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily 4-day saline solution
Study: NCT01438775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: 2.5 mg NX-1207 in 10 mL saline vehicle
Study: NCT04362189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSC
Description: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02972593

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and blood products for transfusion
Description: Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and blood products for transfusion
Description: Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
Study: NCT03203304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg every two weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg every two weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg every six weeks by IV infusion
Study: NCT02718625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Santyl
Description: Collagenase ointment applied topically

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SoloSite®
Description: SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
Study: NCT01266109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management-Family Engagement (CM-FAM)
Description: Evidence-based outpatient intervention for adolescent substance use
Study: NCT02870218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoking research cigarettes with e-cigarette
Description: Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
Study: NCT00926185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution
Study: NCT03648411

Intervention type: GENETIC
Intervention: Drug resistance molecular markers
Description: Proportion of the drug resistance molecular markers will be found-out and compared.

Intervention type: GENETIC
Intervention: Drug resistance molecular markers
Description: Proportion of the drug resistance molecular markers will be found-out and compared.
Study: NCT01951872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based treatment for caffeine dependence
Description: Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based treatment for caffeine dependence
Description: Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
Study: NCT01905306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided implant planning
Study: NCT01266109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Services (US)
Description: Typical community-based substance abuse treatment services
Study: NCT00119028

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Depression Care Quality Improvement Implementation
Description: We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
Study: NCT01905306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free hand implants placement
Study: NCT00783549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an undetermined dose of GSK1292263
Description: GSK investigational product or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascending dose of GSK1292263
Description: Ascending dose based on target exposures or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascending dose of GSK1292263
Description: An ascending dose based on target exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascending dose of GSK1292263
Description: An ascending dose based on target exposures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascending dose of GSK1292263
Description: An ascending dose based on target exposure
Study: NCT04064372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful response to adversity brief training
Description: Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengths-based response to adversity brief training
Description: Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
Study: NCT02374073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Massage
Description: The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapy
Description: therapeutic exercises, analgesic electrotherapy and cryotherapy
Study: NCT02399124

Intervention type: DEVICE
Group type: OTHER
Intervention: PROSENSE™
Description: single arm, open label, PROSENSE™ treatment
Study: NCT02398136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT03353987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings
Study: NCT00475553

Intervention type: OTHER
Group type: OTHER
Intervention: remove ring if bleeding or spotting occurs more than 5 days
Description: Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
Study: NCT02374073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapy
Description: therapeutic exercises, analgesic electrotherapy and cryotherapy
Study: NCT03928340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: 40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: 40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
Study: NCT01522118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100; InSightec
Description: Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens
Study: NCT04333875

Intervention type: DEVICE
Intervention: TAVR or SAVR
Description: Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
Study: NCT03564327

Intervention type: PROCEDURE
Intervention: Wide antrum circle ablation
Description: As standard hospital policy

Intervention type: PROCEDURE
Intervention: External electric cardioversion
Description: Three attempts (200-250 joules)
Study: NCT02485860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melectis G
Study: NCT03878160

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Interview
Description: Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Interview
Description: Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Interview
Description: Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
Study: NCT03026205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARMS-I
Study: NCT02152540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Placebo Device that simulates active rTMS treatment
Study: NCT00834392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking exercise
Study: NCT04543630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor augmentation
Description: Sinus floor augmentaion using the lateral window technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation
Description: Sinus floor augmentaion using the lateral window technique
Study: NCT04233840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101
Study: NCT03872336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental labetalol dose
Description: Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
Study: NCT03035422

Intervention type: DRUG
Group type: OTHER
Intervention: Sequential Packaging (SET)
Description: Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)

Intervention type: DRUG
Group type: OTHER
Intervention: Transfusion graft
Description: Graft of peripheral stem cells is preferred at D0

Intervention type: DRUG
Group type: OTHER
Intervention: Prevention of GVHD
Description: * Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)
Study: NCT02870218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine discrimination thresholds
Description: Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
Study: NCT03035422

Intervention type: DRUG
Group type: OTHER
Intervention: Care supports
Description: According to the protocols of each center

Intervention type: DRUG
Group type: OTHER
Intervention: Lymphocyte injection of prophylactic donor (PDLI)
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II
Study: NCT02809937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: low-dose dexmedetomidine infusion
Study: NCT04480749

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Access to Facility based Syphilis Testing
Description: List of facilities where syphilis testing can be accessed
Study: NCT00475553

Intervention type: OTHER
Group type: OTHER
Intervention: If bleeding does not remove ring
Description: Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
Study: NCT02752919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study: NCT04480749

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Access to Facility based Syphilis Testing
Description: List of facilities where syphilis testing can be accessed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Syphilis Self-Test
Description: Rapid Treponemal Test kit
Study: NCT01576224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark
Description: To be removed during training exercises three to five times a day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark
Description: To be removed during training exercises three to five times a day